These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 508558)

  • 21. Some observations on the changes in capillary resistance in oral contraceptive users.
    Zaki K; Younis MN; Razek SA; Mekkawi TE; Nour H
    Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):145-51. PubMed ID: 12256025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of incremental dosage regimen of combined oestrogen-progestogen oral contraceptive.
    Brosens IA; Robertson WB; Van Assche FA
    Br Med J; 1974 Dec; 4(5945):643-5. PubMed ID: 4441832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The influence of hormonal contraceptives in the spectrum of free plasma amino acids].
    Klinger G; Gruhn K
    Dtsch Gesundheitsw; 1978; 33(50):2373-7. PubMed ID: 729470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between antibiotic therapy and contraceptive medication.
    Bainton R
    Oral Surg Oral Med Oral Pathol; 1986 May; 61(5):453-5. PubMed ID: 3459119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma levels of active ingredients after single and repeated administration of a new oral contraceptive containing 2 mg of cyproterone acetate and 50 micrograms of ethinyl estradiol (DIANE) to five young women.
    Düsterberg B; Hümpel M; Wendt H
    Acta Obstet Gynecol Scand Suppl; 1979; 88():27-31. PubMed ID: 294111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives.
    Fels H; Steward R; Melamed A; Granat A; Stanczyk FZ; Mishell DR
    Contraception; 2013 Jun; 87(6):732-7. PubMed ID: 23352800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of d-norgestrel after oral administration.
    Weiner E; Victor A; Johansson ED
    Contraception; 1976 Nov; 14(5):563-70. PubMed ID: 987892
    [No Abstract]   [Full Text] [Related]  

  • 28. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum lipid studies in women using combination type of oral contraceptives.
    Vaidya R; Purandare VN; Nain S; Gupta K; Rajwade N; Sheth UK
    J Obstet Gynaecol India; 1979 Jun; 29(3):644-6. PubMed ID: 12335922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical and biochemical effects of two combination oral contraceptive agents.
    Sapire KE; Berger GM; Maritz JS
    S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives.
    Bowles SM; Mills RJ
    Ann Clin Biochem; 1981 Jul; 18(Pt 4):226-31. PubMed ID: 7197136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of hormonal contraceptives on menstrual and reproductive function of women].
    Dubnitskaia LV; Sotnikova EI
    Akush Ginekol (Mosk); 1990 Apr; (4):57-60. PubMed ID: 1696071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma concentrations of ethinylestradiol and D-norgestrel during two immediate postabortal oral contraceptive cycles.
    Lähteenmäki P; Nilsson CG
    Contraception; 1978 Jan; 17(1):9-17. PubMed ID: 627151
    [No Abstract]   [Full Text] [Related]  

  • 35. [Oral contraceptive agents and antithrombin III].
    Kamenov V; Nalbanski B
    Akush Ginekol (Sofiia); 1990; 29(1):60-3. PubMed ID: 1695492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined hormonal contraception in cycles artificially extended].
    Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
    Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative data on the liver- and lipid metabolism influencing effects of Anteovin.
    Pilishegyi J
    Ther Hung; 1987; 35(2):71-6. PubMed ID: 3438865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition.
    Down RH; Whiting MJ; Watts JM; Jones W
    Gut; 1983 Mar; 24(3):253-9. PubMed ID: 6826111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical observations with Rigevidon.
    Bálint S
    Ther Hung; 1980; 28(2):75-8. PubMed ID: 7466718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.